Rebuild Medicine

Rebuild Medicine is a biotechnology company focused on developing regenerative cell therapies to treat chronic and life-threatening diseases. A spin-out from the University of Cambridge, the company utilizes a proprietary bio-scaffold technology to transplant functional cells, such as hepatocytes or pancreatic islets, into patients. This platform is designed to improve cell engraftment, survival, and function while potentially eliminating the need for long-term immunosuppression. Rebuild Medicine's lead programs target liver failure and Type 1 diabetes, aiming to restore organ function through the delivery of healthy, lab-grown cells. The company leverages world-class expertise in transplant surgery and stem cell biology to address the global shortage of donor organs. By providing an off-the-shelf cellular solution, Rebuild Medicine seeks to transform the treatment landscape for patients with end-stage organ disease.